The cell sheet-based gene therapy market size has grown rapidly in recent years. It will grow from $0.68 billion in 2025 to $0.78 billion in 2026 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to increasing advancements in tissue engineering research, early adoption of regenerative medicine techniques, growth in cell-based therapeutic studies, improvements in gene delivery technologies, expansion of translational research initiatives.
The cell sheet-based gene therapy market size is expected to see rapid growth in the next few years. It will grow to $1.34 billion in 2030 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to increasing demand for localized regenerative therapies, rising clinical trials in gene-modified cell therapies, expansion of oncology and cardiology applications, growing investments in advanced tissue engineering, increasing focus on precision regenerative medicine. Major trends in the forecast period include expansion of multilayered and co-culture cell sheet technologies, rising focus on localized gene expression therapies, growing integration of regenerative medicine approaches, increased use of stem-cell derived cell sheets, enhanced focus on tissue integration and longevity.
The increasing prevalence of chronic and degenerative diseases is expected to drive growth in the cell sheet-based gene therapy market. Chronic and degenerative diseases are long-term conditions, including cardiovascular disorders, neurodegenerative diseases, diabetes, and genetic disorders, that progressively damage tissues and organs and require ongoing therapeutic intervention. The prevalence of these conditions is rising due to expanding aging populations and increasing life expectancy across both developed and developing economies. Cell sheet-based gene therapy supports regenerative treatment approaches for chronic and degenerative diseases by enabling localized tissue repair and sustained gene delivery through layered living cell constructs, which can enhance tissue integration and long-term therapeutic outcomes. For instance, in April 2025, according to the International Diabetes Federation (IDF), a Belgium-based non-profit organization, 589 million people worldwide were living with diabetes in 2024, a number projected to increase to 853 million by 2050. Therefore, the rising prevalence of chronic and degenerative diseases is driving the growth of the cell sheet-based gene therapy market.
Leading companies operating in the cell sheet-based gene therapy market are focusing on developing innovative solutions such as autologous gene-corrected cell sheet products to improve regenerative medicine outcomes, treatment precision, and long-term tissue repair by combining engineered cells with scaffold-free sheet constructs for targeted gene delivery and wound healing. Autologous gene-corrected cell sheet products refer to therapies in which a patient’s own cells are genetically modified ex vivo, expanded into sheet constructs that preserve cell-to-cell interactions and extracellular matrix integrity, and applied directly to damaged tissues to promote functional integration and durable therapeutic effects. For example, in April 2025, Abeona Therapeutics Inc., a US-based biopharmaceutical company, received approval from the Food and Drug Administration (FDA), a US-based federal agency, for zevaskyn (prademagene zamikeracel), developed to treat wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Zevaskyn delivers the functional COL7A1 gene through genetically corrected cell sheets, promotes clinically meaningful wound healing and pain reduction with a single application, and supports sustained type VII collagen expression at wound sites, positioning it as a breakthrough regenerative therapy and a reference model for future cell sheet-based gene therapy innovations.
In December 2023, Fondazione ENEA Tech e Biomedical, an Italy-based law foundation and investment firm, acquired Holostem Terapie Avanzate S.r.l. for an undisclosed amount. Through this acquisition, the foundation aims to safeguard and advance regenerative medicine capabilities while strengthening research and development in epithelial stem cell-based therapies within the advanced cell and gene therapy domain. Holostem Terapie Avanzate S.r.l. is an Italy-based biotechnology company specializing in the development and manufacturing of cell sheet-based gene and cell therapy products, including epithelial stem cell medicinal products for the treatment of rare and severe diseases.
Major companies operating in the cell sheet-based gene therapy market are Hitachi Ltd., Thermo Fisher Scientific, Fujifilm Cellular Dynamics Inc. (FCDI) (FUJIFILM Holdings Corporation), Lonza Group AG, teijin regenet co. ltd., Terumo Corporation, Nikon CeLL innovation Co. Ltd., Rohto Pharmaceutical Co. Ltd., BioBridge Global, AGC Biologics, Shibuya Corporation (Shibuya Kogyo Co. Ltd.), National Resilience Inc., Takara Bio Inc., Japan Tissue Engineering Co. Ltd. (J-TEC), Medipost Co. Ltd., Cell Therapies Pty Ltd, CellSeed Inc., SCTbio, Abeona Therapeutics Inc., Foundation ENEA Tech, Cyto-Facto Inc., ENCELL Co. Ltd.
Tariffs are influencing the cell sheet-based gene therapy market by increasing costs of imported cell culture substrates, gene delivery vectors, bioprocessing tools, and precision fabrication equipment. Research institutions and biotech companies in North America and Europe are most affected due to reliance on specialized imported materials, while Asia-Pacific faces higher costs in experimental therapy development. These tariffs are increasing development expenses and extending research timelines. However, they are also encouraging domestic production of cell culture materials, regional innovation, and localized manufacturing of supporting gene therapy technologies.
The cell sheet-based gene therapy market research report is one of a series of new reports that provides cell sheet-based gene therapy market statistics, including cell sheet-based gene therapy industry global market size, regional shares, competitors with a cell sheet-based gene therapy market share, detailed cell sheet-based gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cell sheet-based gene therapy industry. This cell sheet-based gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cell sheet-based gene therapy is a treatment strategy that integrates gene delivery with engineered layers of living cells to enable localized and prolonged gene expression at the intended site. This approach maintains natural cell-to-cell interactions and extracellular matrix structures, improving cell viability, tissue integration, and functional consistency following transplantation. It supports targeted tissue repair and sustained therapeutic gene activity while reducing systemic distribution and unintended biological responses.
The primary cell-sheet types of cell sheet-based gene therapy include monolayer cell-sheet type, co-culture cell-sheet type, multilayered cell-sheet type, and other cell-sheet types. Monolayer cell-sheet type refers to a single layer of living cells engineered and cultured to deliver therapeutic genes to target tissues. These products utilize technologies such as cell sheet-based engineering techniques and gene delivery methods. They are derived from sources including autologous cells, allogenic cells, and stem-cell derived cells. They are applied across areas including oncology, ophthalmology, genetic disorders, cardiology, and other applications, and are used by end users including hospitals and clinics, research and academic institutions, biotechnology and pharmaceutical companies, and other end users.
The cell sheet-based gene therapy market consists of revenues earned by entities providing services such as targeted tissue regeneration, sustained gene delivery, and wound healing enhancement. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell sheet-based gene therapy market also includes sales of cell culture substrates, gene delivery vectors, processing tools, and supporting technologies used in the fabrication and application of therapeutic cell sheets. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The cell sheet-based gene therapy market size is expected to see rapid growth in the next few years. It will grow to $1.34 billion in 2030 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to increasing demand for localized regenerative therapies, rising clinical trials in gene-modified cell therapies, expansion of oncology and cardiology applications, growing investments in advanced tissue engineering, increasing focus on precision regenerative medicine. Major trends in the forecast period include expansion of multilayered and co-culture cell sheet technologies, rising focus on localized gene expression therapies, growing integration of regenerative medicine approaches, increased use of stem-cell derived cell sheets, enhanced focus on tissue integration and longevity.
The increasing prevalence of chronic and degenerative diseases is expected to drive growth in the cell sheet-based gene therapy market. Chronic and degenerative diseases are long-term conditions, including cardiovascular disorders, neurodegenerative diseases, diabetes, and genetic disorders, that progressively damage tissues and organs and require ongoing therapeutic intervention. The prevalence of these conditions is rising due to expanding aging populations and increasing life expectancy across both developed and developing economies. Cell sheet-based gene therapy supports regenerative treatment approaches for chronic and degenerative diseases by enabling localized tissue repair and sustained gene delivery through layered living cell constructs, which can enhance tissue integration and long-term therapeutic outcomes. For instance, in April 2025, according to the International Diabetes Federation (IDF), a Belgium-based non-profit organization, 589 million people worldwide were living with diabetes in 2024, a number projected to increase to 853 million by 2050. Therefore, the rising prevalence of chronic and degenerative diseases is driving the growth of the cell sheet-based gene therapy market.
Leading companies operating in the cell sheet-based gene therapy market are focusing on developing innovative solutions such as autologous gene-corrected cell sheet products to improve regenerative medicine outcomes, treatment precision, and long-term tissue repair by combining engineered cells with scaffold-free sheet constructs for targeted gene delivery and wound healing. Autologous gene-corrected cell sheet products refer to therapies in which a patient’s own cells are genetically modified ex vivo, expanded into sheet constructs that preserve cell-to-cell interactions and extracellular matrix integrity, and applied directly to damaged tissues to promote functional integration and durable therapeutic effects. For example, in April 2025, Abeona Therapeutics Inc., a US-based biopharmaceutical company, received approval from the Food and Drug Administration (FDA), a US-based federal agency, for zevaskyn (prademagene zamikeracel), developed to treat wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Zevaskyn delivers the functional COL7A1 gene through genetically corrected cell sheets, promotes clinically meaningful wound healing and pain reduction with a single application, and supports sustained type VII collagen expression at wound sites, positioning it as a breakthrough regenerative therapy and a reference model for future cell sheet-based gene therapy innovations.
In December 2023, Fondazione ENEA Tech e Biomedical, an Italy-based law foundation and investment firm, acquired Holostem Terapie Avanzate S.r.l. for an undisclosed amount. Through this acquisition, the foundation aims to safeguard and advance regenerative medicine capabilities while strengthening research and development in epithelial stem cell-based therapies within the advanced cell and gene therapy domain. Holostem Terapie Avanzate S.r.l. is an Italy-based biotechnology company specializing in the development and manufacturing of cell sheet-based gene and cell therapy products, including epithelial stem cell medicinal products for the treatment of rare and severe diseases.
Major companies operating in the cell sheet-based gene therapy market are Hitachi Ltd., Thermo Fisher Scientific, Fujifilm Cellular Dynamics Inc. (FCDI) (FUJIFILM Holdings Corporation), Lonza Group AG, teijin regenet co. ltd., Terumo Corporation, Nikon CeLL innovation Co. Ltd., Rohto Pharmaceutical Co. Ltd., BioBridge Global, AGC Biologics, Shibuya Corporation (Shibuya Kogyo Co. Ltd.), National Resilience Inc., Takara Bio Inc., Japan Tissue Engineering Co. Ltd. (J-TEC), Medipost Co. Ltd., Cell Therapies Pty Ltd, CellSeed Inc., SCTbio, Abeona Therapeutics Inc., Foundation ENEA Tech, Cyto-Facto Inc., ENCELL Co. Ltd.
Tariffs are influencing the cell sheet-based gene therapy market by increasing costs of imported cell culture substrates, gene delivery vectors, bioprocessing tools, and precision fabrication equipment. Research institutions and biotech companies in North America and Europe are most affected due to reliance on specialized imported materials, while Asia-Pacific faces higher costs in experimental therapy development. These tariffs are increasing development expenses and extending research timelines. However, they are also encouraging domestic production of cell culture materials, regional innovation, and localized manufacturing of supporting gene therapy technologies.
The cell sheet-based gene therapy market research report is one of a series of new reports that provides cell sheet-based gene therapy market statistics, including cell sheet-based gene therapy industry global market size, regional shares, competitors with a cell sheet-based gene therapy market share, detailed cell sheet-based gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cell sheet-based gene therapy industry. This cell sheet-based gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cell sheet-based gene therapy is a treatment strategy that integrates gene delivery with engineered layers of living cells to enable localized and prolonged gene expression at the intended site. This approach maintains natural cell-to-cell interactions and extracellular matrix structures, improving cell viability, tissue integration, and functional consistency following transplantation. It supports targeted tissue repair and sustained therapeutic gene activity while reducing systemic distribution and unintended biological responses.
The primary cell-sheet types of cell sheet-based gene therapy include monolayer cell-sheet type, co-culture cell-sheet type, multilayered cell-sheet type, and other cell-sheet types. Monolayer cell-sheet type refers to a single layer of living cells engineered and cultured to deliver therapeutic genes to target tissues. These products utilize technologies such as cell sheet-based engineering techniques and gene delivery methods. They are derived from sources including autologous cells, allogenic cells, and stem-cell derived cells. They are applied across areas including oncology, ophthalmology, genetic disorders, cardiology, and other applications, and are used by end users including hospitals and clinics, research and academic institutions, biotechnology and pharmaceutical companies, and other end users.
The cell sheet-based gene therapy market consists of revenues earned by entities providing services such as targeted tissue regeneration, sustained gene delivery, and wound healing enhancement. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell sheet-based gene therapy market also includes sales of cell culture substrates, gene delivery vectors, processing tools, and supporting technologies used in the fabrication and application of therapeutic cell sheets. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Cell Sheet-based Gene Therapy Market Characteristics
3. Cell Sheet-based Gene Therapy Market Supply Chain Analysis
4. Global Cell Sheet-based Gene Therapy Market Trends and Strategies
5. Cell Sheet-based Gene Therapy Market Analysis Of End Use Industries
7. Global Cell Sheet-based Gene Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Cell Sheet-based Gene Therapy Total Addressable Market (TAM) Analysis for the Market
9. Cell Sheet-based Gene Therapy Market Segmentation
10. Cell Sheet-based Gene Therapy Market Regional and Country Analysis
11. Asia-Pacific Cell Sheet-based Gene Therapy Market
12. China Cell Sheet-based Gene Therapy Market
13. India Cell Sheet-based Gene Therapy Market
14. Japan Cell Sheet-based Gene Therapy Market
15. Australia Cell Sheet-based Gene Therapy Market
16. Indonesia Cell Sheet-based Gene Therapy Market
17. South Korea Cell Sheet-based Gene Therapy Market
18. Taiwan Cell Sheet-based Gene Therapy Market
19. South East Asia Cell Sheet-based Gene Therapy Market
20. Western Europe Cell Sheet-based Gene Therapy Market
21. UK Cell Sheet-based Gene Therapy Market
22. Germany Cell Sheet-based Gene Therapy Market
23. France Cell Sheet-based Gene Therapy Market
24. Italy Cell Sheet-based Gene Therapy Market
25. Spain Cell Sheet-based Gene Therapy Market
26. Eastern Europe Cell Sheet-based Gene Therapy Market
27. Russia Cell Sheet-based Gene Therapy Market
28. North America Cell Sheet-based Gene Therapy Market
29. USA Cell Sheet-based Gene Therapy Market
30. Canada Cell Sheet-based Gene Therapy Market
31. South America Cell Sheet-based Gene Therapy Market
32. Brazil Cell Sheet-based Gene Therapy Market
33. Middle East Cell Sheet-based Gene Therapy Market
34. Africa Cell Sheet-based Gene Therapy Market
36. Cell Sheet-based Gene Therapy Market Competitive Landscape and Company Profiles
37. Cell Sheet-based Gene Therapy Market Other Major and Innovative Companies
41. Cell Sheet-based Gene Therapy Market High Potential Countries, Segments and Strategies
42. Appendix
Executive Summary
Cell Sheet-Based Gene Therapy Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses cell sheet-based gene therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cell sheet-based gene therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cell sheet-based gene therapy market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Cell-Sheet Type: Monolayer Cell-Sheet Type; Co-Culture Cell-Sheet Type; Multilayered Cell-Sheet Type; Other Cell-Sheet Types2) By Technology Type: Cell Sheet-Based Engineering Techniques; Gene Delivery Methods
3) By Source Type: Autologous; Allogenic; Stem-Cell Derived
4) By Application: Oncology; Ophthalmology; Genetic Disorders; Cardiology; Other Applications
5) By End-User: Hospitals and Clinics; Research and Academic Institutions; Biotech and Pharma Companies; Other End-Users
Subsegments:
1) By Monolayer Cell-Sheet Type: Cardiomyocyte Sheets; Epithelial Cell Sheets; Mesenchymal Stem Cell Sheets; Other Monolayer Cell Sheets2) By Co-Culture Cell-Sheet Type: Fibroblast + Stem Cell Sheets; Endothelial + Smooth Muscle Cell Sheets; Other Co-Culture Combinations
3) By Multilayered Cell-Sheet Type: Triple-Layered Sheets; Double-Layered Sheets; Other Multilayered Configurations
4) By Other Cell-Sheet Types: Genetically Modified Cell Sheets; Hybrid Cell Sheets; Other Novel Or Experimental Sheets
Companies Mentioned: Hitachi Ltd.; Thermo Fisher Scientific; Fujifilm Cellular Dynamics Inc. (FCDI) (FUJIFILM Holdings Corporation); Lonza Group AG; teijin regenet co. ltd.; Terumo Corporation; Nikon CeLL innovation Co. Ltd.; Rohto Pharmaceutical Co. Ltd.; BioBridge Global; AGC Biologics; Shibuya Corporation (Shibuya Kogyo Co. Ltd.); National Resilience Inc.; Takara Bio Inc.; Japan Tissue Engineering Co. Ltd. (J-TEC); Medipost Co. Ltd.; Cell Therapies Pty Ltd; CellSeed Inc.; SCTbio; Abeona Therapeutics Inc.; Foundation ENEA Tech; Cyto-Facto Inc.; ENCELL Co. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Cell Sheet-Based Gene Therapy market report include:- Hitachi Ltd.
- Thermo Fisher Scientific
- Fujifilm Cellular Dynamics Inc. (FCDI) (FUJIFILM Holdings Corporation)
- Lonza Group AG
- teijin regenet co. ltd.
- Terumo Corporation
- Nikon CeLL innovation Co. Ltd.
- Rohto Pharmaceutical Co. Ltd.
- BioBridge Global
- AGC Biologics
- Shibuya Corporation (Shibuya Kogyo Co. Ltd.)
- National Resilience Inc.
- Takara Bio Inc.
- Japan Tissue Engineering Co. Ltd. (J-TEC)
- Medipost Co. Ltd.
- Cell Therapies Pty Ltd
- CellSeed Inc.
- SCTbio
- Abeona Therapeutics Inc.
- Foundation ENEA Tech
- Cyto-Facto Inc.
- ENCELL Co. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | March 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 0.78 Billion |
| Forecasted Market Value ( USD | $ 1.34 Billion |
| Compound Annual Growth Rate | 14.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
